Pamela J. Cramer - 07 Nov 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Signature
/s/ Stephen Vander Stoep, attorney-in-fact for Pamela J. Cramer
Issuer symbol
RYTM
Transactions as of
07 Nov 2025
Transactions value $
-$2,000,740
Form type
4
Filing time
12 Nov 2025, 16:30:12 UTC
Previous filing
29 Jul 2025
Next filing
24 Nov 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cramer Pamela J. Chief Human Resources Officer C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON /s/ Stephen Vander Stoep, attorney-in-fact for Pamela J. Cramer 12 Nov 2025 0001873517

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise $167K +8.81K +42.3% $19.02 29.6K 07 Nov 2025 Direct
transaction RYTM Common Stock Options Exercise $71.7K +10.5K +35.61% $6.80 40.2K 07 Nov 2025 Direct
transaction RYTM Common Stock Sale -$1.91M -19.4K -48.18% $98.82 20.8K 07 Nov 2025 Direct F1
transaction RYTM Common Stock Options Exercise $23.9K +3.52K +16.89% $6.80 24.3K 10 Nov 2025 Direct
transaction RYTM Common Stock Sale -$352K -3.52K -14.45% $100.00 20.8K 10 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Options (Right to Buy) Options Exercise $0 -8.81K -62.62% $0.00 5.26K 07 Nov 2025 Common Stock 8.81K $19.02 Direct F2
transaction RYTM Stock Options (Right to Buy) Options Exercise $0 -10.5K -59.99% $0.00 7.04K 07 Nov 2025 Common Stock 10.5K $6.80 Direct F3
transaction RYTM Stock Options (Right to Buy) Options Exercise $0 -3.52K -49.96% $0.00 3.52K 10 Nov 2025 Common Stock 3.52K $6.80 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025.
F2 The stock option is fully vested.
F3 The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.